EP1841417A2 - Spm 927 pour la thérapie adjuvante de la schizophrenie - Google Patents
Spm 927 pour la thérapie adjuvante de la schizophrenieInfo
- Publication number
- EP1841417A2 EP1841417A2 EP06706448A EP06706448A EP1841417A2 EP 1841417 A2 EP1841417 A2 EP 1841417A2 EP 06706448 A EP06706448 A EP 06706448A EP 06706448 A EP06706448 A EP 06706448A EP 1841417 A2 EP1841417 A2 EP 1841417A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- use according
- aryl
- unsubstituted
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000000980 schizophrenia Diseases 0.000 title claims abstract description 70
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 43
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 title claims description 36
- 229960002623 lacosamide Drugs 0.000 title description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 99
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 91
- 238000011282 treatment Methods 0.000 claims abstract description 83
- 239000000164 antipsychotic agent Substances 0.000 claims abstract description 76
- 230000002265 prevention Effects 0.000 claims abstract description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 230000000561 anti-psychotic effect Effects 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 104
- -1 alkyl heterocyclic Chemical group 0.000 claims description 75
- 125000003118 aryl group Chemical group 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 42
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 40
- 125000004432 carbon atom Chemical group C* 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 37
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 229960004170 clozapine Drugs 0.000 claims description 33
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 33
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 17
- 229960003036 amisulpride Drugs 0.000 claims description 16
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims description 16
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 208000018737 Parkinson disease Diseases 0.000 claims description 14
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 14
- 229960005017 olanzapine Drugs 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 229960001534 risperidone Drugs 0.000 claims description 14
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 14
- 208000020925 Bipolar disease Diseases 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 12
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 12
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 12
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 12
- 206010003805 Autism Diseases 0.000 claims description 12
- 208000020706 Autistic disease Diseases 0.000 claims description 12
- 229960004372 aripiprazole Drugs 0.000 claims description 12
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 12
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 12
- 229960004431 quetiapine Drugs 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 229960004940 sulpiride Drugs 0.000 claims description 12
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 12
- 229960000607 ziprasidone Drugs 0.000 claims description 12
- 229960004496 zotepine Drugs 0.000 claims description 12
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 12
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 9
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 8
- 208000007848 Alcoholism Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 7
- 208000012661 Dyskinesia Diseases 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 206010021036 Hyponatraemia Diseases 0.000 claims description 7
- 206010026749 Mania Diseases 0.000 claims description 7
- 208000036626 Mental retardation Diseases 0.000 claims description 7
- 208000019022 Mood disease Diseases 0.000 claims description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 7
- 208000016620 Tourette disease Diseases 0.000 claims description 7
- 206010001584 alcohol abuse Diseases 0.000 claims description 7
- 208000025746 alcohol use disease Diseases 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 7
- 230000036033 hyponatraemia Effects 0.000 claims description 7
- 206010022437 insomnia Diseases 0.000 claims description 7
- 208000022821 personality disease Diseases 0.000 claims description 7
- 206010036067 polydipsia Diseases 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- GMDCDXMAFMEDAG-CHHFXETESA-N (S,S)-asenapine maleate Chemical compound OC(=O)\C=C/C(O)=O.O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 GMDCDXMAFMEDAG-CHHFXETESA-N 0.000 claims description 4
- PXUIZULXJVRBPC-UHFFFAOYSA-N 1'-[3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]hexahydro-2H-spiro[imidazo[1,2-a]pyridine-3,4'-piperidin]-2-one Chemical compound C12=CC(Cl)=CC=C2CCC2=CC=CC=C2N1CCCN1CCC2(C(NC3CCCCN32)=O)CC1 PXUIZULXJVRBPC-UHFFFAOYSA-N 0.000 claims description 4
- BTFMCMVEUCGQDX-UHFFFAOYSA-N 1-[10-[3-[4-(2-hydroxyethyl)-1-piperidinyl]propyl]-2-phenothiazinyl]ethanone Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(CCO)CC1 BTFMCMVEUCGQDX-UHFFFAOYSA-N 0.000 claims description 4
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 claims description 4
- GUJRSXAPGDDABA-NSHDSACASA-N 3-bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(OC)C=CC(Br)=C1OC GUJRSXAPGDDABA-NSHDSACASA-N 0.000 claims description 4
- ICAXEUYZCLRXKY-UHFFFAOYSA-N 7-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCCOC=3C=C4OC=C(C(C4=CC=3)=O)CO)=NOC2=C1 ICAXEUYZCLRXKY-UHFFFAOYSA-N 0.000 claims description 4
- QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 claims description 4
- ANDGGVOPIJEHOF-UHFFFAOYSA-N CX-516 Chemical compound C=1C=C2N=CC=NC2=CC=1C(=O)N1CCCCC1 ANDGGVOPIJEHOF-UHFFFAOYSA-N 0.000 claims description 4
- ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 claims description 4
- 229950007013 abaperidone Drugs 0.000 claims description 4
- 229960001615 asenapine maleate Drugs 0.000 claims description 4
- 229960003532 fluspirilene Drugs 0.000 claims description 4
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims description 4
- 229960003162 iloperidone Drugs 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 229960003894 mosapramine Drugs 0.000 claims description 4
- CVCDAZZJQWLXHM-UHFFFAOYSA-N mosapramine dihydrochloride Chemical compound Cl.Cl.C12=CC(Cl)=CC=C2CCC2=CC=CC=C2N1CCCN1CCC2(C(NC3CCCCN32)=O)CC1 CVCDAZZJQWLXHM-UHFFFAOYSA-N 0.000 claims description 4
- 229950010634 ocaperidone Drugs 0.000 claims description 4
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 claims description 4
- 229960002195 perazine Drugs 0.000 claims description 4
- 229950004193 perospirone Drugs 0.000 claims description 4
- GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 claims description 4
- 229960004265 piperacetazine Drugs 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 229960005197 quetiapine fumarate Drugs 0.000 claims description 4
- 229960003448 remoxipride Drugs 0.000 claims description 4
- 229960003474 ziprasidone hydrochloride Drugs 0.000 claims description 4
- ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 3
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 229960002841 oxypertine Drugs 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 229960000652 sertindole Drugs 0.000 claims description 3
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- XCVDGQBGMARFRY-GFCCVEGCSA-N (2r)-2-acetamido-n-[(3-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC(F)=C1 XCVDGQBGMARFRY-GFCCVEGCSA-N 0.000 claims description 2
- PVNGTPGYSFGJIH-GFCCVEGCSA-N (2r)-2-acetamido-n-[(4-fluorophenyl)methyl]-3-methoxypropanamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=C(F)C=C1 PVNGTPGYSFGJIH-GFCCVEGCSA-N 0.000 claims description 2
- VEEHBRVUEHYHQQ-CYBMUJFWSA-N (2r)-2-acetamido-n-benzyl-3-ethoxypropanamide Chemical compound CCOC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VEEHBRVUEHYHQQ-CYBMUJFWSA-N 0.000 claims description 2
- 239000004593 Epoxy Chemical group 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000003838 furazanyl group Chemical group 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 abstract description 13
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 description 20
- 230000006977 prepulse inhibition Effects 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 230000009471 action Effects 0.000 description 14
- 239000001961 anticonvulsive agent Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 229940125681 anticonvulsant agent Drugs 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 229940127236 atypical antipsychotics Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 208000004547 Hallucinations Diseases 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000036278 prepulse Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229960001848 lamotrigine Drugs 0.000 description 5
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 5
- KTOYYUONFQWSMW-UHFFFAOYSA-N pipotiazine palmitate Chemical compound C1CC(CCOC(=O)CCCCCCCCCCCCCCC)CCN1CCCN1C2=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C21 KTOYYUONFQWSMW-UHFFFAOYSA-N 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 5
- 229940102566 valproate Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 229960003878 haloperidol Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000024188 startle response Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 3
- 206010012239 Delusion Diseases 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- 206010052804 Drug tolerance Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 3
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 229950001988 biriperone Drugs 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 229960001184 clopenthixol Drugs 0.000 description 3
- 231100000868 delusion Toxicity 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000026781 habituation Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960001861 melperone Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 150000002990 phenothiazines Chemical class 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 125000001453 quaternary ammonium group Chemical group 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 150000005075 thioxanthenes Chemical class 0.000 description 3
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 description 2
- KRVOJOCLBAAKSJ-RDTXWAMCSA-N (2R,3R)-nemonapride Chemical compound C1=C(Cl)C(NC)=CC(OC)=C1C(=O)N[C@H]1[C@@H](C)N(CC=2C=CC=CC=2)CC1 KRVOJOCLBAAKSJ-RDTXWAMCSA-N 0.000 description 2
- VCRGLZYPNNAVRP-JTQLQIEISA-N (4s)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid Chemical compound CC1(C)CCC(NC(=O)[C@@H](N)CCC(O)=O)CC1 VCRGLZYPNNAVRP-JTQLQIEISA-N 0.000 description 2
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 2
- YCNCIZWAGQTWBI-IBGZPJMESA-N (s)-1-(4-fluorophenyl)-4-(3,4,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indol-2(1h)-yl)butan-1-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1C[C@@H]2CC(C3=CC=CC=C3N3)=C3CN2CC1 YCNCIZWAGQTWBI-IBGZPJMESA-N 0.000 description 2
- MQHYXXIJLKFQGY-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methylpiperidin-1-ium-1-yl)butan-1-one;chloride Chemical compound [Cl-].C1CC(C)CC[NH+]1CCCC(=O)C1=CC=C(F)C=C1 MQHYXXIJLKFQGY-UHFFFAOYSA-N 0.000 description 2
- MDLAAYDRRZXJIF-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-piperidinol Chemical compound C1CC(O)(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 MDLAAYDRRZXJIF-UHFFFAOYSA-N 0.000 description 2
- XDBMBHVYXPBOPL-UHFFFAOYSA-N 2-[4-(9-fluoro-3-propan-2-yl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]ethanol Chemical compound C12=CC(C(C)C)=CC=C2SC2=CC(F)=CC=C2CC1N1CCN(CCO)CC1 XDBMBHVYXPBOPL-UHFFFAOYSA-N 0.000 description 2
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 2
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- KAAZGXDPUNNEFN-UHFFFAOYSA-N Clotiapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2SC2=CC=C(Cl)C=C12 KAAZGXDPUNNEFN-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- LRWSFOSWNAQHHW-UHFFFAOYSA-N Fluphenazine enanthate Chemical compound C1CN(CCOC(=O)CCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 LRWSFOSWNAQHHW-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- GUTXTARXLVFHDK-UHFFFAOYSA-N Haloperidol decanoate Chemical compound C1CC(OC(=O)CCCCCCCCC)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 GUTXTARXLVFHDK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 2
- GQWNECFJGBQMBO-UHFFFAOYSA-N Molindone hydrochloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 2
- JTVPZMFULRWINT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-methoxy-5-methylsulfonylbenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC(S(C)(=O)=O)=CC=C1OC JTVPZMFULRWINT-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- UNRHXEPDKXPRTM-UHFFFAOYSA-N Sultopride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC=C1OC UNRHXEPDKXPRTM-UHFFFAOYSA-N 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- JSZILQVIPPROJI-CEXWTWQISA-N [(2R,3R,11bS)-3-(diethylcarbamoyl)-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] acetate Chemical compound C1CC2=CC(OC)=C(OC)C=C2[C@H]2N1C[C@@H](C(=O)N(CC)CC)[C@H](OC(C)=O)C2 JSZILQVIPPROJI-CEXWTWQISA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WNTYBHLDCKXEOT-UHFFFAOYSA-N acetophenazine Chemical compound C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 WNTYBHLDCKXEOT-UHFFFAOYSA-N 0.000 description 2
- 229960000276 acetophenazine Drugs 0.000 description 2
- 125000000033 alkoxyamino group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229940124604 anti-psychotic medication Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002507 benperidol Drugs 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 229960004564 benzquinamide Drugs 0.000 description 2
- 229960004037 bromperidol Drugs 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- DVLBYTMYSMAKHP-UHFFFAOYSA-N butaperazine Chemical compound C12=CC(C(=O)CCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 DVLBYTMYSMAKHP-UHFFFAOYSA-N 0.000 description 2
- 229960000608 butaperazine Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229950009852 carfenazine Drugs 0.000 description 2
- TVPJGGZLZLUPOB-SPIKMXEPSA-N carphenazine maleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C12=CC(C(=O)CC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 TVPJGGZLZLUPOB-SPIKMXEPSA-N 0.000 description 2
- NWPJLRSCSQHPJV-UHFFFAOYSA-N carpipramine Chemical compound C1CN(CCCN2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 NWPJLRSCSQHPJV-UHFFFAOYSA-N 0.000 description 2
- 229960000700 carpipramine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 2
- 229960001552 chlorprothixene Drugs 0.000 description 2
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 2
- JFRLWWDJCFYFSU-UHFFFAOYSA-N clomacran Chemical compound C1=C(Cl)C=C2C(CCCN(C)C)C3=CC=CC=C3NC2=C1 JFRLWWDJCFYFSU-UHFFFAOYSA-N 0.000 description 2
- 229950001885 clomacran Drugs 0.000 description 2
- XRYLGRGAWQSVQW-UHFFFAOYSA-N clorotepine Chemical compound C1CN(C)CCN1C1C2=CC(Cl)=CC=C2SC2=CC=CC=C2C1 XRYLGRGAWQSVQW-UHFFFAOYSA-N 0.000 description 2
- 229950011192 clorotepine Drugs 0.000 description 2
- 229960003864 clotiapine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 description 2
- 229960004278 cyamemazine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MSYUMPGNGDNTIQ-UHFFFAOYSA-N dixyrazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC(C)CN1CCN(CCOCCO)CC1 MSYUMPGNGDNTIQ-UHFFFAOYSA-N 0.000 description 2
- 229960005146 dixyrazine Drugs 0.000 description 2
- 229960000394 droperidol Drugs 0.000 description 2
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229960005220 fluanisone Drugs 0.000 description 2
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002419 flupentixol Drugs 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 2
- 229960001374 fluphenazine decanoate Drugs 0.000 description 2
- 229960000787 fluphenazine enanthate Drugs 0.000 description 2
- 229960001258 fluphenazine hydrochloride Drugs 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229960005007 haloperidol decanoate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000003104 hexanoyl group Chemical class O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical class [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 2
- 229960000589 loxapine succinate Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 2
- 229960000300 mesoridazine Drugs 0.000 description 2
- CRJHBCPQHRVYBS-UHFFFAOYSA-N mesoridazine besylate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 CRJHBCPQHRVYBS-UHFFFAOYSA-N 0.000 description 2
- 229960003664 mesoridazine besylate Drugs 0.000 description 2
- BRABPYPSZVCCLR-UHFFFAOYSA-N methopromazine Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC(OC)=CC=C3SC2=C1 BRABPYPSZVCCLR-UHFFFAOYSA-N 0.000 description 2
- 229950008620 methopromazine Drugs 0.000 description 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 2
- 229940042053 methotrimeprazine Drugs 0.000 description 2
- BAQLUVXNKOTTHU-UHFFFAOYSA-N metofenazate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCN2CCN(CCCN3C4=CC(Cl)=CC=C4SC4=CC=CC=C43)CC2)=C1 BAQLUVXNKOTTHU-UHFFFAOYSA-N 0.000 description 2
- 229950010788 metofenazate Drugs 0.000 description 2
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 2
- 229960004758 minaprine Drugs 0.000 description 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 2
- 229960004644 moclobemide Drugs 0.000 description 2
- 229960004938 molindone Drugs 0.000 description 2
- 229960004684 molindone hydrochloride Drugs 0.000 description 2
- 229960000758 moperone Drugs 0.000 description 2
- AGAHNABIDCTLHW-UHFFFAOYSA-N moperone Chemical compound C1=CC(C)=CC=C1C1(O)CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 AGAHNABIDCTLHW-UHFFFAOYSA-N 0.000 description 2
- 229950007573 neboglamine Drugs 0.000 description 2
- 229950011108 nemonapride Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- CBHCDHNUZWWAPP-UHFFFAOYSA-N pecazine Chemical compound C1N(C)CCCC1CN1C2=CC=CC=C2SC2=CC=CC=C21 CBHCDHNUZWWAPP-UHFFFAOYSA-N 0.000 description 2
- 229950007538 pecazine Drugs 0.000 description 2
- 229960004505 penfluridol Drugs 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- LUALIOATIOESLM-UHFFFAOYSA-N periciazine Chemical compound C1CC(O)CCN1CCCN1C2=CC(C#N)=CC=C2SC2=CC=CC=C21 LUALIOATIOESLM-UHFFFAOYSA-N 0.000 description 2
- 229960000769 periciazine Drugs 0.000 description 2
- WYRWAVVTDKZRIJ-UHFFFAOYSA-N perimetazine Chemical compound C12=CC(OC)=CC=C2SC2=CC=CC=C2N1CC(C)CN1CCC(O)CC1 WYRWAVVTDKZRIJ-UHFFFAOYSA-N 0.000 description 2
- 229950007697 perimetazine Drugs 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 229940068151 pipothiazine Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- 229960003598 promazine Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- JTTAUPUMOLRVRA-UHFFFAOYSA-N prothipendyl Chemical group C1=CN=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JTTAUPUMOLRVRA-UHFFFAOYSA-N 0.000 description 2
- 229960000957 prothipendyl Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
- 229950001675 spiperone Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- FLGCRGJDQJIJAW-UHFFFAOYSA-N sulforidazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)(=O)=O)=CC=C2SC2=CC=CC=C21 FLGCRGJDQJIJAW-UHFFFAOYSA-N 0.000 description 2
- 229950010000 sulforidazine Drugs 0.000 description 2
- 229960004724 sultopride Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- AIUHRQHVWSUTGJ-UHFFFAOYSA-N thiopropazate Chemical compound C1CN(CCOC(=O)C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 AIUHRQHVWSUTGJ-UHFFFAOYSA-N 0.000 description 2
- 229960004728 thiopropazate Drugs 0.000 description 2
- VZYCZNZBPPHOFY-UHFFFAOYSA-N thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 description 2
- 229960003397 thioproperazine Drugs 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- NZFNXWQNBYZDAQ-UHFFFAOYSA-N thioridazine hydrochloride Chemical compound Cl.C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C NZFNXWQNBYZDAQ-UHFFFAOYSA-N 0.000 description 2
- 229960004098 thioridazine hydrochloride Drugs 0.000 description 2
- 229960000882 thiothixene hydrochloride Drugs 0.000 description 2
- 229960005344 tiapride Drugs 0.000 description 2
- 229960005013 tiotixene Drugs 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- BXDAOUXDMHXPDI-UHFFFAOYSA-N trifluoperazine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 BXDAOUXDMHXPDI-UHFFFAOYSA-N 0.000 description 2
- 229960000315 trifluoperazine hydrochloride Drugs 0.000 description 2
- 229960002341 trifluperidol Drugs 0.000 description 2
- GPMXUUPHFNMNDH-UHFFFAOYSA-N trifluperidol Chemical compound C1CC(O)(C=2C=C(C=CC=2)C(F)(F)F)CCN1CCCC(=O)C1=CC=C(F)C=C1 GPMXUUPHFNMNDH-UHFFFAOYSA-N 0.000 description 2
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 2
- 229960003904 triflupromazine Drugs 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- OXAUOBQMCDIVPQ-IOXNKQMXSA-N zuclopenthixol acetate Chemical compound C1CN(CCOC(=O)C)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 OXAUOBQMCDIVPQ-IOXNKQMXSA-N 0.000 description 2
- 229960003939 zuclopenthixol acetate Drugs 0.000 description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- VLZBRVJVCCNPRJ-KPHUOKFYSA-N (1S,2S)-2-[(1S)-1-amino-1-carboxy-2-(9H-xanthen-9-yl)ethyl]-1-cyclopropanecarboxylic acid Chemical compound C([C@@H]1[C@](CC2C3=CC=CC=C3OC3=CC=CC=C32)(N)C(O)=O)[C@@H]1C(O)=O VLZBRVJVCCNPRJ-KPHUOKFYSA-N 0.000 description 1
- SGBCQENKTXKIRD-MRXNPFEDSA-N (2r)-2-acetamido-n-benzyl-2-phenylacetamide Chemical compound O=C([C@H](NC(=O)C)C=1C=CC=CC=1)NCC1=CC=CC=C1 SGBCQENKTXKIRD-MRXNPFEDSA-N 0.000 description 1
- GELJVTSEGKGLDF-QDSMGTAFSA-N (2s)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C([C@H]1COC=2C=CC3=C(C=2O1)CC(N3)=O)NCC1=CC=CC=C1 GELJVTSEGKGLDF-QDSMGTAFSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- HPMRFMKYPGXPEP-SNVBAGLBSA-N (S)-idazoxan Chemical compound N1CCN=C1[C@@H]1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-SNVBAGLBSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical group C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- UUTRFZNTTSPNOY-UHFFFAOYSA-N 1-[3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]-4-piperidin-1-ylpiperidine-4-carboxamide;dihydrochloride Chemical compound [Cl-].[Cl-].C1C[NH+](CCCN2C3=CC(Cl)=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)[NH+]1CCCCC1 UUTRFZNTTSPNOY-UHFFFAOYSA-N 0.000 description 1
- DQZZUZZSEFHBSL-UHFFFAOYSA-N 1-[3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl]-4-piperidin-1-ylpiperidine-4-carboxamide;hydron;dichloride;hydrate Chemical compound O.Cl.Cl.C1CN(CCCN2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 DQZZUZZSEFHBSL-UHFFFAOYSA-N 0.000 description 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- WFPIAZLQTJBIFN-BLLMUTORSA-N 2-[4-[(3e)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1CC\C=C/1C2=CC(Cl)=CC=C2SC2=CC=CC=C2\1 WFPIAZLQTJBIFN-BLLMUTORSA-N 0.000 description 1
- YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 1
- WPLANNRKFDHEKD-UHFFFAOYSA-N 2-amino-n-benzyl-3-methoxypropanamide Chemical compound COCC(N)C(=O)NCC1=CC=CC=C1 WPLANNRKFDHEKD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- XDKITDYMWBKDKU-UHFFFAOYSA-N 3-(9h-xanthen-9-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)C3=CC=CC=C3OC2=C1 XDKITDYMWBKDKU-UHFFFAOYSA-N 0.000 description 1
- BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 150000000644 6-membered heterocyclic compounds Chemical class 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001000171 Chira Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- CUCHJCMWNFEYOM-UHFFFAOYSA-N Ethyl loflazepate Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)OCC)N=C1C1=CC=CC=C1F CUCHJCMWNFEYOM-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- OFVXPDXXVSGEPX-UHFFFAOYSA-N Flutoprazepam Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C11)=NCC(=O)N1CC1CC1 OFVXPDXXVSGEPX-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- QRUAPADZILXULG-WKIKZPBSSA-N Zuclopenthixol decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 QRUAPADZILXULG-WKIKZPBSSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- 125000005276 alkyl hydrazino group Chemical group 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- YCNCIZWAGQTWBI-UHFFFAOYSA-N biriperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC2CC(C3=CC=CC=C3N3)=C3CN2CC1 YCNCIZWAGQTWBI-UHFFFAOYSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- YFLRYAVDPKONNX-UHFFFAOYSA-N buramate Chemical compound OCCOC(=O)NCC1=CC=CC=C1 YFLRYAVDPKONNX-UHFFFAOYSA-N 0.000 description 1
- 229950009824 buramate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960003275 carpipramine dihydrochloride Drugs 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- ODQWQRRAPPTVAG-BOPFTXTBSA-N cis-doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 ODQWQRRAPPTVAG-BOPFTXTBSA-N 0.000 description 1
- 229960000584 citalopram hydrobromide Drugs 0.000 description 1
- QAZKXHSIKKNOHH-UHFFFAOYSA-N clocapramine Chemical compound C1CN(CCCN2C3=CC(Cl)=CC=C3CCC3=CC=CC=C32)CCC1(C(=O)N)N1CCCCC1 QAZKXHSIKKNOHH-UHFFFAOYSA-N 0.000 description 1
- 229950001534 clocapramine Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- KAEHGTRAXGGNBL-HSZRJFAPSA-N devazepide Chemical compound O=C([C@@H](NC(=O)C=1N=C2[CH]C=CC=C2C=1)N=1)N(C)C2=CC=CC=C2C=1C1=CC=CC=C1 KAEHGTRAXGGNBL-HSZRJFAPSA-N 0.000 description 1
- 229950007317 devazepide Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940028937 divalproex sodium Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229960002496 duloxetine hydrochloride Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 229960004759 ethyl loflazepate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- XFVRBYKKGGDPAJ-UHFFFAOYSA-N farampator Chemical compound C1=CC2=NON=C2C=C1C(=O)N1CCCCC1 XFVRBYKKGGDPAJ-UHFFFAOYSA-N 0.000 description 1
- 229950010629 farampator Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
- 229950009299 flutoprazepam Drugs 0.000 description 1
- 229960002107 fluvoxamine maleate Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000001339 gustatory effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- NEKCRUIRPWNMLK-SCIYSFAVSA-N lurasidone hydrochloride Chemical compound Cl.C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 NEKCRUIRPWNMLK-SCIYSFAVSA-N 0.000 description 1
- 229960002863 lurasidone hydrochloride Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 125000005358 mercaptoalkyl group Chemical group 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- JFTURWWGPMTABQ-UHFFFAOYSA-N n,n-dimethyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCN(C)C)C1=CC=CS1 JFTURWWGPMTABQ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960005290 opipramol Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 229960002776 pipamperone Drugs 0.000 description 1
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 1
- 229960003252 pipotiazine Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 229960003770 reboxetine Drugs 0.000 description 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229950000425 sabcomeline Drugs 0.000 description 1
- IQWCBYSUUOFOMF-QTLFRQQHSA-N sabcomeline Chemical compound C1CC2[C@@H](C(/C#N)=N/OC)CN1CC2 IQWCBYSUUOFOMF-QTLFRQQHSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- KKNIUBFRGPFELP-UHFFFAOYSA-N secretolin Chemical compound N=1C=CNC=1CC(N)C(=O)NC(CO)C(=O)NC(CC(O)=O)C(=O)NCC(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O)C(C)O)CC1=CC=CC=C1 KKNIUBFRGPFELP-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- CFOYBMUYCBSDAL-UHFFFAOYSA-N spiclomazine Chemical compound C12=CC(Cl)=CC=C2SC2=CC=CC=C2N1CCCN(CC1)CCC21NC(=O)CS2 CFOYBMUYCBSDAL-UHFFFAOYSA-N 0.000 description 1
- 229950000231 spiclomazine Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229950011332 talnetant Drugs 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005296 thioaryloxy group Chemical group 0.000 description 1
- YDLQKLWVKKFPII-UHFFFAOYSA-N timiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=S)CC1 YDLQKLWVKKFPII-UHFFFAOYSA-N 0.000 description 1
- 229950000809 timiperone Drugs 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- 229960000783 zuclopenthixol decanoate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is directed to the use of a class of peptide compounds for the prevention, alleviation or/and treatment of a disease that is treated with antipsychotics, in particular psychosis, more particular schizophrenia, in an add-on therapy to at least one antipsychotic.
- the present invention is directed to the use of a class of peptide compounds for the prevention, alleviation or/and treatment of schizophrenia, bipolar disorder, autism, attention deficit hyperactivity disorder, psychosis, psychosis associated with schizophrenia, bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia, Huntington's Disease, Tourette's syndrom, Parkinson's disease, or/and dopaminergic therapy of Parkinson's disease, preferably wherein psychosis is associated with schizophrenia, in an add-on therapy to at least one antipsychotic.
- Certain peptides are known to exhibit central nervous system (CNS) activity and are useful in the treatment of epilepsy and other CNS disorders. These peptides which are described in the U.S. Patent No. 5,378,729 have the Formula (Ia):
- R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl lower alkyl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, and R is unsubstituted or is substituted with at least one electron withdrawing group or electron donating group;
- Ri is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic lower alkyl, heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, each unsubstituted or substituted with an electron donating group or an electron withdrawing group;
- R 2 and R 3 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl lower alkyl, aryl, heterocyclic, heterocyclic lower alkyl, lower alkyl heterocyclic, lower cycloalkyl, lower cycloalkyl lower alkyl, or Z-Y wherein R 2 and R 3 may be unsubstituted or substituted with at least one electron withdrawing group or electron donating group;
- Z is O, S, S(O) 3 , NR 4 , PR 4 or a chemical bond
- Y is hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, lower alkynyl, halo, heterocyclic, heterocyclic lower alkyl, and Y may be unsubstituted or substituted with an electron donating group or an electron withdrawing group, provided that when Y is halo, Z is a chemical bond, or ZY taken together is NR 4 NR 5 R 7 , NR 4 OR 5 , ONR 4 R 7 , OPR 4 R 5 , PR 4 OR 5 , SNR 4 R 7 , NR 4 SR 7 , SPR 4 R 5 or PR 4 SR 7 , NR 4 PR 5 R 6 or PR 4 NR 5 R 7 ,
- R 4 , R 5 and R 6 are independently hydrogen, lower alkyl, aryl, aryl lower alkyl, lower alkenyl, or lower alkynyl, wherein R 4 , R 5 and R 6 may be unsubstituted or substituted with an electron withdrawing group or an electron donating group; and
- R 7 is R 6 or COOR 8 or COR 8 ;
- Re is hydrogen or lower alkyl, or aryl lower alkyl, and the aryl or alkyl group may be unsubstituted or substituted with an electron withdrawing group or an electron donating group;
- U.S. Patent No. 5,773,475 also discloses additional compounds useful for treating CNS disorders. These compounds are N-benzyl-2-amino-3- methoxy-propionamide having the Formula (Ha):
- WO 02/074297 relates to the use of a compound according to Formula (Ha) wherein Ar is phenyl which may be substituted by at least one halo, R 3 is lower alkoxy containing 1-3 carbon atoms and Ri is methyl for the preparation of pharmaceutical compositions useful for the treatment of allodynia related to peripheral neuropathic pain.
- WO 02/074784 relates to the use of a compound having Formula (Ia) or/and Formula (Ha) showing antinociceptive properties for treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain, e.g. rheumatoid arthritic pain or/and secondary inflammatory osteo-arthritic pain.
- non neuropathic inflammatory pain e.g. rheumatoid arthritic pain or/and secondary inflammatory osteo-arthritic pain.
- Psychosis in particular schizophrenia, is a state of mental impairment marked by following symptoms:
- Hallucinations are perceptions that occur without connection to an appropriate source. Hallucinations can occur in any sensory form - auditory (sound), visual (sight), tactile (touch), gustatory (taste), and olfactory (smell). Auditory hallucinations, particularly the experience of hearing voices that other people do not hear, are a common and often prominent feature of psychosis.
- Delusions are false personal beliefs that are not subject to reason or contradictory evidence and are not explained by a person's usual cultural concepts.
- Psychosis is considered to be a symptom of severe mental illness, but not a diagnosis in itself. Although it is not exclusively linked to any particular psychological or physical state, it is particularly associated with schizophrenia, bipolar disorder and severe clinical depression. There are also several physical circumstances that can induce a psychotic state, including electrolyte disorder, urinary tract infections in the elderly, pain syndromes, drug toxicity, and drug withdrawal (especially alcohol, barbiturates, and sometimes benzodiazepines) as well as infections of or injuries to the brain (these psychoses are now more commonly referred to as organic mental disorders).
- Psychosis is a common condition in schizophrenia, marked by the typical, above mentioned symptoms.
- people with schizophrenia often show "blunted” or “fiat” affect. This refers to a severe reduction in emotional expressiveness.
- Schizophrenia is a chronic, severe, and disabling brain disease found all over the world. Approximately 1 percent of the population develops schizophrenia during their lifetime. The severity of the symptoms and long- lasting, chronic pattern of schizophrenia often cause a high degree of disability. People with schizophrenia have a higher rate of suicide than the general population. Approximately 10 percent of people with schizophrenia (especially younger adult males) commit suicide. The first signs of schizophrenia often appear as confusing, or even shocking, changes in behavior. This sudden onset of severe psychotic symptoms is referred to as an "acute" phase of schizophrenia.
- Clinically effective antipsychotic agents include tricyclic phenothiazines, thioxanthenes, and dibenzepines, as well as butyrophenones and congeners, other heterocyclics and experimental benzamides.
- Virtually all of these drugs block D 2 -dopamine receptors and reduce dopamine neurotransmission in forebrain; some of these drugs, in particular the atypical antipsychotics, also interact with Dr and D 4 -dopaminergic, 5-H ⁇ 2A- and 5-HT 2 c-serotonergic and alpha-adrenergic receptors (Goodman & Gilman's, The Pharmacological Basis of Therapeutics, 10 th edition, McGraw-Hill, 2001: Summary of chapter 20 (p. 485)).
- Antagonism of dopamine-mediated synaptic neurotransmission is an important action of antipsychotic drugs (same document, p. 493, left column, 2 nd para).
- clozapine A number of new antipsychotic agents (the so-called “atypical antipsychotics”) have been introduced since 1990. The first of these, clozapine, has been shown to be more effective than other antipsychotics, although the possibility of severe side effects - in particular, a condition called agranulocytosis (loss of the white blood cells that fight infection) - requires that patients be monitored with blood tests every one or two weeks. Even newer antipsychotic agents, such as risperidone and olanzapine are safer than the older drugs or clozapine, and they also may be better tolerated. They may or may not treat the illness as well as clozapine, however.
- Antipsychotic agents are often very effective in treating certain symptoms of schizophrenia, particularly hallucinations and delusions; unfortunately, the drugs may not be as helpful with other symptoms, such ⁇ as reduced motivation and emotional expressiveness.
- lacosamide In contrast to current anticonvulsants, lacosamide potentially has a unique but yet unknown molecular mechanism of action. Lacosamide does not directly interact with a variety of known GABA receptor subtypes, nor does it directly interact with a variety of known glutamate receptor subtypes. In particular, lacosamide does not inhibit voltage-gated sodium or calcium channels and does not potentiate potassium currents.
- the use of compounds of Formula (Ib) or/and Formula (lib) for treatment of psychosis, in particular schizophrenia or/and psychosis associated with schizophrenia, in an add-on therapy to at least one antipsychotic agent has not been reported.
- the present invention concerns the use of said compound(s) of Formulae (Ib) or/and (lib) for the preparation of a pharmaceutical composition for the prevention, alleviation or/and treatment of a disease treated with an antipsychotic, in particular psychosis, more particular in the course of schizophrenia, in an add-on therapy to at least one antipsychotic.
- Prepulse inhibition in mice is a model of predictive value for psychosis associated with e.g. schizophrenia, bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia, Huntington's Disease, Tourette's syndrom, Parkinson's disease, or/and dopaminergic therapy of Parkinson's disease.
- psychosis associated with e.g. schizophrenia, bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia, Huntington's Disease, Tourette's syndrom,
- ..antipsychotic agent or ..antipsychotic refers to any compound known in the art for prevention, alleviation or treatment of psychosis, including without limitation: (-)-isofloxythepin, (+-)-idazoxan monohydrochloride, (+)-isofloxythepin, 1 ,2-benzisoxazole-3- methanesulfonamide, monosodium salt, 1H-isoindole-a,3(2H)-dione, 2-[4-[4- (1 ,2-benzisothiazol-3-yl)-1 -piperazinyl]buryl]-hexahydro-, monohydrochloride, (3aR,7aS)-rel-, 2(1H)-quinolinone, 1-[3-[4-(3- chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy- (OPC 14523
- antipsychotic or “antipsychotic agent” as used here is meant to comprise classical or so-called typical antipsychotics, also referred to as classical or typical neuroleptics, as well as atypical antipsychotics, also referred to as atypical neuroleptics.
- Examples for classical antipsychotics are acetophenazine, benperidol, benzquinamide, biriperone, bromoperidol, butaperazine, butyrophenones, carphenazine, centbutindole, chlorpromazine, chlorpromazine hydrochloride, chlorprothixene, clomacran, clopenthixol, clothiapine, cyamemazine, dibenzoxazepines, dihydroindolones, dixyrazine, droperidol, fluanisone, flupentixol, fluphenazine, fluphenazine decanoate, fluphenazine enanthate, fluphenazine hydrochloride, haloperidol, haloperidol decanoate, isofloxythepin, levomepromazine, loxapine succinate, melperone, melperone hydrochloride, mepazine, mes
- Examples for atypical antipsychotics are abaperidone, aminosultopride, amisulpride, ampalex, aripiprazole, asenapine maleate, clozapine, fluspirilene, iloperidone, mosapramine, mosapramine dihydrochloride, ocaperidone, olanzapine, oxypertine, .
- antipsychotic further comprises dopamine antagonists, preferably D 2 antagonists.
- antipsychotic or "antipsychotic agent” as used here preferably does not comprise drugs that, although they might also be used in the therapy of psychosis, are no antipsychotics as defined above, such as for example anticonvulsants (such as carbamazepine, valproate, lamotrigine), antidepressants, such as tri- and tetracyclic antidepressants (for example amitryptiline, clomipramine, doxepine, imipramine, trimipramine, nortriptyline, desipramine, maprotiline, trazodone), selective serotonine- reuptake inhibitors (for example citaloprame, fluoxetine, fluvoxamine, paroxetine, sertraline), selective noradrenaline-reuptake inhibitors (for example reboxetine), serotonine-noradrenaline-reuptake inhibitors (for example venlafaxine, duloxetine), serotonine-noradrenaline
- Doses of typical dopamine antagonists which may be employed in the present invention are:
- the present invention refers to a specific combination of lacosamide with at least one of the antipsychotics as indicated above, more particular with at least one dopamine antagonist, which may be at least one D2 antagonist, even more particular with at least one atypical antipsychotic such as at least one atypical antipsychotic as defined above, most particular clozapine, risperidone, aripiprazole, quetiapine, olanzapine, ziprasidone, sulpiride, amisulpride or/and zotepine.
- dopamine antagonist which may be at least one D2 antagonist
- at least one atypical antipsychotic such as at least one atypical antipsychotic as defined above, most particular clozapine, risperidone, aripiprazole, quetiapine, olanzapine, ziprasidone, sulpiride, amisulpride or/and zotepine.
- An add-on therapy according to the present invention for the prevention, alleviation or/and treatment of a disease treated with an antipsychotic, in particular psychosis, more particular schizophrenia or/and psychosis associated with schizophrenia is the co-administration of at least one compound of Formulae (Ib) or/and (lib) with at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis, in particular schizophrenia, in order to increase the efficacy, decrease the side effects or/and enhance the onset of action of the antipsychotic medication, for example.
- co-administration refers to a plurality of agents that, when administered to a subject together or separately, are co-active in bringing therapeutic benefit to the subject. Such co-administration is also referred to as "combination therapy,” “co-therapy,” “adjunctive therapy” or “add-on therapy.”
- one agent can potentiate or enhance the therapeutic effect of another, or reduce an adverse side effect of another, or one or more agents can be effectively administered at a lower dose than when used alone, or can provide greater therapeutic benefit than when used alone, or can complementarity address different aspects, symptoms or etiological factors of a disease or condition.
- Co-administration comprises administration of the agents in amounts sufficient to achieve or/and maintain therapeutically effective concentrations, e.g. plasma concentrations, in the subject in need thereof.
- Co-administration comprises simultaneous or/and subsequent administration.
- Simultaneous administration comprises administration of the agents as a single or as different compositions (see below) "at the same time" within the treatment period.
- Subsequent administration comprises administration of the agents
- Administration "at the same time” includes administration of the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis and the compound(s) of Formulae (Ib) or/and (lib) literally “at the same time”, but also includes administration directly one after another.
- Administration "at intervals” includes administration of the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis and the compound(s) of Formulae (Ib) or/and (lib) at an interval of 1 h at the maximum, preferably 6 h at the maximum, more preferably 12 h at the maximum, even more preferably 1 day at the maximum, and most preferably 1 month at the maximum.
- (Ib) or/and (lib) may be formulated in one pharmaceutical preparation (single dose form) for administration at the same time or may be formulated in two distinct preparations (separate dose form) for administration at the same time or at intervals, as described in the preferred embodiments below for example.
- the two distinct preparations in the separate dose form may be administered by the same route or by different routes.
- Separate dose forms can optionally be co-packaged, for example in a single coritainer or in a plurality of containers within a single outer package, or co- presented in separate packaging ("common presentation").
- a kit is contemplated comprising, in separate containers, the at least one antipsychotic and the at least one compound of Formulae (Ib) or/and (lib).
- the at least one antipsychotic and the at least one compound of Formulae (Ib) or/and (lib) are separately packaged and available for sale independently of one another, but are co-marketed or co-promoted for use according to the invention.
- the separate dose forms may also be presented to a subject separately and independently, for use according to the invention.
- the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis and the compound(s) of Formulae (Ib) or/and (lib) may be administered with the same or with different schedules on a daily, weekly or monthly basis. Therefore, the administration interval of the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis and the compound(s) of Formulae (Ib) or/and (lib) may depend on the administration schedules or/and on the dosage forms.
- the compounds of Formulae (Ib) or/and (lib) are used for the preparation of a pharmaceutical composition comprising (a) at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis, and (b) at least one compound of Formulae (Ib) or/and (lib).
- the at least one antipsychotic agent useful for the prevention, alleviation or treatment of psychosis may be a dopamine antagonist, preferably a D 2 antagonist, more preferably an atypical antipsychotic agent, even more preferably an atypical antipsychotic as defined above, and most preferably the agent is clozapine, risperidone, aripiprazole, quetiapine, olanzapine, ziprasidone, sulpiride, amisulpride or/and zotepine.
- the compounds of Formulae (Ib) or/and (lib) are used for the preparation of a pharmaceutical composition comprising a single dose form comprising at least one compound according to Formula (Ib) or/and Formula (lib) and at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis in the form of one composition.
- a first composition comprising at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis, and
- a commercially available composition of an antipsychotic agent useful for prevention, alleviation or/and treatment of psychosis may be administered to a subject in need thereof. Therefore, in this preferred embodiment, the compounds of Formulae (Ib) or/and (lib) are used for the preparation of a pharmaceutical composition comprising at least one compound according to Formula (Ib) or/and Formula (lib) and not comprising an antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis.
- the use according to the present invention may comprise the preparation of a pharmaceutical composition for administration of the at least one compound of Formulae (Ib) or/and (lib) and the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis at the same time or at intervals, as defined above.
- a compound according to the invention has the general Formula (Ib)
- R is hydrogen, alkyl, alkenyl, alkynyl, aryl, aryl alkyl, heterocyclic, heterocyclic alkyl, alkyl heterocyclic, cycloalkyl or cycloalkyl alkyl, and R is unsubstituted or is substituted with at least one electron withdrawing group, and/or at least one electron donating group;
- Ri is hydrogen or alkyl, alkenyl, alkynyl, aryl alkyl, aryl, heterocyclic alkyl, alkyl heterocyclic, heterocyclic, cycloalkyl, cycloalkyl alkyl, each unsubstituted or substituted with at least one electron donating group and/or at least one electron withdrawing group;
- R 2 and R 3 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl alkyl, aryl, halo, heterocyclic, heterocyclic alkyl, alkyl heterocyclic, cycloalkyl, cycloalkyl alkyl, or Z-Y wherein R 2 and R 3 may be unsubstituted or substituted with at least one electron withdrawing group and/or at least one electron donating group;
- Z is O, S, S(O) 3 , NR 4 , NR'e, PR 4 or a chemical bond;
- Y is hydrogen, alkyl, aryl, aryl alkyl, alkenyl, alkynyl, halo, heterocyclic, heterocyclic alkyl, alkyl heterocyclic and Y may be unsubstituted or substituted with at least one electron donating group and/or at least one electron withdrawing group, provided that when Y is halo, Z is a chemical bond, or
- ZY taken together is NR 4 NR 5 R 7 , NR 4 OR 5 , ONR 4 R 7 , OPR 4 R 5 , PR 4 OR 5 , SNR 4 R 7 , NR 4 SR 7 , SPR 4 R 5 , PR 4 SR 7 , NR 4 PR 5 R 6 , PR 4 NR 5 R 7 Or N + R 5 R 6 R 7 ,
- R'e is hydrogen, alkyl, alkenyl, or alkynyl which may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;
- R 4 , R 5 and R 6 are independently hydrogen, alkyl, aryl, aryl alkyl, alkenyl, or alkynyl, wherein R 4 , R 5 and R 6 may independently be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;
- R 7 is R 6 or COOR 8 or COR 8 , which R 7 may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;
- R 8 is hydrogen or alkyl, or aryl alkyl, and the aryl or alkyl group may be unsubstituted or substituted with at least one electron withdrawing group or/and at least one electron donating group;
- the compound according to the invention has the general Formula (lib) H H H Ar-CHr-N I-C-C I-N I-C-Ri O Il R I 3 O Il
- Ar is aryl, especially phenyl, which is unsubstituted or substituted with at least one substituent independently selected from the group consisting of hydrogen, halo, alkyl, alkenyl, alkynyl, nitro, carboxy, formyl, carboxyamido, aryl, quaternary ammonium, haloalkyl, aryl alkanoyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aryloxy, mercapto, alkylthio, alkylmercapto, and disulfide;
- R 3 is selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, N-alkoxy-N-alkylamino, and N-alkoxyamino; and R 1 is alkyl.
- Ar is aryl, especially phenyl, which is unsubstituted or substituted with at least one halo;
- R 3 is -CH 2 -Q, wherein Q is lower alkoxy; and
- Ri is lower alkyl, especially methyl.
- the present invention is also directed to a pharmaceutical composition
- a pharmaceutical composition comprising at least one compound according to Formula (Ib) or/and Formula (lib) useful for the prevention, alleviation or/and treatment of a disease that can be treated with an antipsychotic, in particular psychosis, in an add-on therapy to at least one antipsychotic agent.
- the pharmaceutical composition comprises
- the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis may be a dopamine antagonist, preferably a D 2 antagonist, more preferably an atypical antipsychotic agent, even more preferably an atypical antipsychotic as defined above, and most preferably the agent is clozapine, risperidone, aripiprazole, quetiapine, olanzapine, ziprasidone, sulpiride, amisulpride or/and zotepine.
- the pharmaceutical composition of the present invention comprises a single dose form comprising at least one compound according to Formula (Ib) or/and Formula (lib) and at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis in the form of one composition.
- the pharmaceutical composition of the present invention comprises a separate dose form comprising (i) a first composition comprising at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis, and (ii) a second composition comprising at least one compound of Formulae (Ib) or/and (lib).
- a commercially available composition of an antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis may be administered to a subject in need thereof. Therefore, in this preferred embodiment, the pharmaceutical composition of the present invention comprises at least one compound according to Formula (Ib) or/and Formula (lib) and does not comprise an antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis.
- the pharmaceutical composition of the present invention may be prepared for administration of the at least one compound of Formulae (Ib) or/and (lib) and the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis at the same time or at intervals, as defined above.
- alkyi (alone or in combination with another term(s)) means a straight- or branched-chain saturated hydrocarbyl substituent preferably containing from 1 to about 20 carbon atoms, more preferably from 1 to about 8 carbon atoms, and even more preferably from 1 to about 6 carbon atoms. Most preferably, alkyl is lower alkyl as defined below.
- lower alkyl groups when used alone or in combination with other groups, are lower alkyl containing from 1 to 6 carbon atoms, especially 1 to 3 carbon atoms, and may be straight chain or branched. These groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl and isomers of pentyl, hexyl and isomers of hexyl, and the like.
- alkoxy (alone or in combination with another term(s)) means an alkylether substituent, i.e., -O-alkyl.
- lower alkoxy groups are lower alkoxy containing from 1 to 6 carbon atoms, especially 1 to 3 carbon atoms, and may be straight chain or branched. These groups include methoxy, ethoxy, propoxy, butoxy, isobutoxy, tert-butoxy, pentoxy, hexoxy and the like.
- aryl alkyl or “aryl lower alkyl” groups include, for example, benzyl, phenylethyl, phenylpropyl, phenylisopropyl, phenylbutyl, diphenylmethyl, 1,1- diphenylethyl, 1 ,2-diphenylethyl, and the like.
- aryl when used alone or in combination, refers to an aromatic group which contains from 6 up to 18 ring carbon atoms and up to a total of 25 carbon atoms and includes the polynuclear aromatics. These aryl groups may be monocyclic, bicyclic, tricyclic or polycyclic and are fused rings.
- a polynuclear aromatic compound as used herein, is meant to encompass bicyclic and tricyclic fused aromatic ring systems containing from 10-18 ring carbon atoms and up to a total of 25 carbon atoms.
- the aryl group includes phenyl, and the polynuclear aromatics e.g., naphthyl, anthracenyl, phenanthrenyl, azulenyl and the like.
- the aryl group also includes groups like ferrocenyl.
- Aryl groups may be unsubstituted or mono or polysubstituted with electron withdrawing or/and electron donating groups as described below.
- alkenyl (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more double bonds and preferably from 2 to about 20 carbon atoms, more preferably from 2 to about 8 carbon atoms, and even more preferably from 2 to about 6 carbon atoms.
- the alkenyl groups, where asymmetric, can have cis or trans configuration. Most preferably, alkenyl is lower alkenyl as defined below.
- “Lower alkenyl” is an alkenyl group containing from 2 to 6 carbon atoms and at least one double bond. These groups may be straight chained or branched and may be in the Z or E form. Such groups include vinyl, propenyl, 1-butenyl, isobutenyl, 2-butenyl, 1-pentenyl, (Z)-2-pentenyl, (E)-2- pentenyl, (Z)-4-methyl-2-pentenyl, (E)-4-methyl-2-pentenyl, pentadienyl, e.g., 1 , 3 or 2,4-pentadienyl, and the like.
- alkynyl (alone or in combination with another term(s)) means a straight- or branched-chain hydrocarbyl substituent containing one or more triple bonds and preferably from 2 to about 20 carbon atoms, more preferably from 2 to about 8 carbon atoms, and even more preferably from 2 to about 6 carbon atoms. Most preferably, alkynyl is lower alkynyl as defined below.
- lower alkynyl is an alkynyl group containing 2 to 6 carbon atoms and may be straight chained as well as branched. It includes such groups as ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-methyl-1- pentynyl, 3-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl and the like.
- lower cycloalkyl or "cycloalkyl” when used alone or in combination is a cycloalkyl group containing from 3 to 18 ring carbon atoms and up to a total of 25 carbon atoms.
- the cycloalkyl groups may be monocyclic, bicyclic, tricyclic, or polycyclic and the rings are fused.
- the cycloalkyl may be completely saturated or partially saturated.
- Cycloalkyl includes the cis or trans forms. Cycloalkyl groups may be unsubstituted or mono or polysubstituted with electron withdrawing or/and electron donating groups as described below. Furthermore, the substituents may either be in endo or exo positions in the bridged bicyclic systems.
- electrospraying and “electron donating” refer to the ability of a substituent to withdraw or donate electrons, respectively, relative to that of hydrogen if the hydrogen atom occupied the same position in the molecule. These terms are well understood by one skilled in the art and are discussed in Advanced Organic Chemistry, by J. March, John Wiley and Sons, New York, NY, pp.16-18 (1985) and the discussion therein is incorporated herein by reference.
- Electron withdrawing groups include halo, including bromo, fluoro, chloro, iodo and the like; nitro, carboxy, alkenyl, alkynyl, formyl, carboxyamido, aryl, quaternary ammonium, haloalkyl such as trifluoromethyl, aryl alkanoyl, carbalkoxy and the like.
- Electron donating groups include such groups as hydroxy, alkoxy, including methoxy, ethoxy and the like; alkyl, such as methyl, ethyl, and the like; amino, alkylamino, di (alkyl) amino, aryloxy such as phenoxy, mercapto, alkylthio, alkylmercapto, disulfide (alkyldithio) and the like.
- alkyl such as methyl, ethyl, and the like
- substituents may be considered to be electron donating or electron withdrawing under different chemical conditions.
- the present invention contemplates any combination of substituents selected from the above-identified groups.
- Carbalkoxy refers to -CO-O-alkyl,
- halo includes fluoro, chloro, bromo, and iodo.
- Alkanoyl alone or in combination with another term(s) means a straight or branched chain alkanoyl substituent preferably containing from 1 to about 20 carbon atoms, more preferably from 1 to about 8 carbon atoms, even more preferably from 1 to about 6 carbon atoms.
- acyl includes lower alkanoyl containing from 1 to 6 carbon atoms and may be straight chains or branched. These groups include, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, tertiary butyryl, pentanoyl and isomers of pentanoyl, and hexanoyl and isomers of hexanoyl.
- a heterocyclic group contains at least one sulfur, nitrogen or oxygen ring atom, but also may include several of said atoms in the ring.
- the heterocyclic groups contemplated by the present invention include heteroaromatics and saturated and partially saturated heterocyclic compounds. These heterocyclics may be monocyclic, bicyclic, tricyclic or polycyclic and are e.g. fused rings. They may preferably contain up to 18 ring atoms and up to a total of 17 ring carbon atoms and a total of up to 25 carbon atoms.
- the heterocyclics are also intended to include the so-called benzoheterocyclics.
- heterocyclics include furyl, thienyl, pyrazolyl, pyrrolyl, methylpyrrolyl, imidazolyl, indolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, piperidyl, pyrrolinyl, piperazinyl, quinolyl, triazolyl, tetrazolyl, isoquinolyl, benzofuryl, benzothienyl, morpholinyl, benzoxazolyl, tetrahydrofuryl, pyranyl, indazolyl, purinyl, indolinyl, pyrazolindinyl, imidazolinyl, imadazolindinyl, pyrrolidinyl, furazanyl, N-methylindolyl, methylfuryl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridyl
- the preferred heterocyclics are thienyl, furyl, pyrrolyl, benzofuryl, benzothienyl, indolyl, methylpyrrolyl, morpholinyl, pyridiyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl.
- the preferred heterocyclic is a 5 or 6- membered heterocyclic compound.
- the especially preferred heterocyclic is furyl, pyridyl, pyrazinyl, imidazolyl, pyrimidinyl, or pyridazinyl.
- the most preferred heterocyclics are furyl and pyridyl.
- n 1
- R is aryl lower alkyl, especially benzyl especially those wherein the phenyl ring thereof is unsubstituted or substituted with electron donating groups or/and electron withdrawing groups, such as halo (e.g., F).
- halo e.g., F
- the preferred Ri is H or lower alkyl.
- the most preferred Ri group is methyl.
- the preferred electron donating substituents or/and electron withdrawing substituents are halo, nitro, alkanoyl, formyl, arylalkanoyl, aryloyl, carboxyl, carbalkoxy, carboxamido, cyano, sulfonyl, sulfoxide, heterocyclic, guanidine, quaternary ammonium, alkenyl, alkynyl, sulfonium salts, hydroxy, alkoxy, alkyl, amino, alkylamino, di(alkyl)amino, amino alkyl, mercapto, mercaptoalkyl, alkylthio, and alkyldithio.
- sulfide encompasses mercapto, mercapto alkyl and alkylthio, while the term disulfide encompasses alkyldithio.
- Especially preferred electron donating or/and electron withdrawing groups are halo or alkoxy, e.g. lower alkoxy, most preferred are fluoro or methoxy.
- These preferred substituents may be present on any one of the groups in Formula (Ib) or/and (lib), e.g. R, Ri, R 2 , R 3 , RA, RS, Re, R'e, R7, Rs and/or R 50 as defined herein.
- the ZY groups representative of R 2 and R 3 include hydroxy, alkoxy, such as methoxy, ethoxy, aryloxy, such as phenoxy; thioalkoxy, such as thiomethoxy, thioethoxy; thioaryloxy such as thiophenoxy; amino; alkylamino, such as methylamino, ethylamino; arylamino, such as anilino; lower dialkylamino, such as, dimethylamino; trialkyl ammonium salt, hydrazino; alkylhydrazino and arylhydrazino, such as N-methylhydrazino, N-phenylhydrazino, carbalkoxy hydrazino, aralkoxycarbonyl hydrazino, aryloxycarbonyl hydrazino, hydroxylamino, such as N-hydroxylamino (-NH-OH), alkoxy amino [(NHORi 8 ) wherein R 18 is
- the preferred heterocyclic groups representative of R 2 and R 3 are monocyclic 5- or 6-membered heterocyclic moieties of the formula:
- n 0 or 1 ;
- R 50 is H or an electron withdrawing group or electron donating group
- A, E, L, J and G are independently CH, or a heteroatom selected from the group consisting of N, O, S; but when n is 0, G is CH 1 or a heteroatom selected from the group consisting of NH, O and S with the proviso that at most two of A, E, L, J and G are heteroatoms.
- the above heteroaromatic moiety is a five membered ring, while if n is 1 , the heterocyclic moiety is a six membered monocyclic heterocyclic moiety.
- the preferred heterocyclic moieties are those aforementioned heterocyclics which are monocyclic.
- the ring depicted hereinabove contains a nitrogen ring atom, then the N- oxide forms are also contemplated to be within the scope of the invention.
- R 2 or R 3 When R 2 or R 3 is a heterocyclic of the above formula, it may be bonded to the main chain by a ring carbon atom. When n is 0, R 2 or R 3 may additionally be bonded to the main chain by a nitrogen ring atom.
- R 2 and R 3 are hydrogen, aryl, e.g., phenyl, aryl alkyl, e.g., benzyl and alkyl.
- R 2 and R 3 may be unsubstituted or mono or poly substituted with electron donating or/and electron withdrawing groups. It is preferred that R 2 and R 3 are independently hydrogen, alkyl, which is either unsubstituted or substituted with electron withdrawing groups or/and electron donating groups, such as alkoxy (e.g., methoxy, ethoxy, and the like), N-hydroxylamino, N-alkylhydroxyamino, N- alkyl-O-alkyl and alkylhydroxyamino.
- alkoxy e.g., methoxy, ethoxy, and the like
- R 2 and R 3 are hydrogen.
- n is one.
- Z is O, NR 4 or PR 4 ; Y is hydrogen or alkyl, e.g. lower alkyl; ZY is NR 4 NR 5 R?,
- n 1
- R 2 is hydrogen and R 3 is alkyl, e.g. lower alkyl which may be substituted or unsubstituted with an electron donating or electron withdrawing group, NR 4 OR 5 , or ONR 4 R 7 ,
- n 1, R 2 is hydrogen and R 3 is alkyl, e.g. lower alkyl which is unsubstituted or substituted with hydroxy or loweralkoxy, NR 4 OR 5 or ONR 4 R 7 , wherein R 4 , R 5 and R 7 are independently hydrogen or alkyl, R is aryl alkyl, which aryl group may be unsubstituted or substituted with an electron withdrawing group and Ri is alkyl, e.g. lower alkyl. In this embodiment it is most preferred that aryl is phenyl, which is unsubstituted or substituted with halo.
- R 2 is hydrogen and R 3 is hydrogen, an alkyl group which is unsubstituted or substituted by at least an electron donating or electron withdrawing group or ZY.
- R 3 is hydrogen, an alkyl group such as methyl, which is unsubstituted or substituted by an electron donating group, or NR 4 OR 5 or ONR 4 R 7 , wherein R 4 , R 5 and R 7 are independently hydrogen or lower alkyl.
- the electron donating group is alkoxy, e.g. lower alkoxy, and especially methoxy or ethoxy.
- R 2 and R 3 are independently hydrogen, alkyl, e.g. lower alkyl, or ZY;
- Z is O, NR 4 or PR 4 ;
- Y is hydrogen or alkyl, e.g. lower alkyl or ZY is NR 4 R 5 R 7 , NR 4 OR 5 , ONR 4 R 7 , NR 4 C-R 5 or NR 4 C-OR 5 .
- R is aryl alkyl, e.g. aryl lower alkyl.
- the most preferred aryl for R is phenyl.
- the most preferred R group is benzyl.
- the aryl group may be unsubstituted or substituted with an electron donating or electron withdrawing group. If the aryl ring in R is substituted, it is most preferred that it is substituted with an electron withdrawing group, especially on the aryl ring.
- the most preferred electron withdrawing group for R is halo, especially fluoro.
- the preferred Ri is lower alkyl, especially methyl.
- R is aryl lower alkyl and Ri is lower alkyl.
- R 2 is hydrogen
- R 3 is hydrogen, an alkyl group, e.g. a lower alkyl group, especially methyl which is substituted by an electron donating or electron withdrawing group or ZY
- R is aryl alkyl, e.g. aryl lower alkyl, such as benzyl, wherein the aryl group is unsubstituted or substituted with an electron donating or electron withdrawing group
- Ri is alkyl, e.g. lower alkyl.
- R 3 is hydrogen, an alkyl group, e.g.
- a lower alkyl group especially methyl, which may be substituted by electron donating group, such as alkoxy, e.g. lower alkoxy, (e.g., methoxy, ethoxy and the like), NR 4 OR 5 or ONR 4 R 7 wherein these groups are defined hereinabove.
- Ar is aryl, especially phenyl, which is unsubstituted or substituted with at least one electron donating group or electron withdrawing group, especially halo,
- Ri is alkyl, especially containing 1-3 carbon atoms
- R 3 is as defined herein, but especially hydrogen, alkyl, e.g. lower alkyl, which is unsubstituted or substituted by at least an electron donating group or electron withdrawing group or ZY. It is even more preferred that R 3 is, in this embodiment, hydrogen, an alkyl group which is unsubstituted or substituted by an electron donating group, NR 4 OR 5 or ONR4R7. It is most preferred that
- R 3 is CH 2 -Q 1 wherein Q is alkoxy, e.g. lower alkoxy, especially containing 1-3 carbon atoms; NR 4 OR 5 or ONR 4 R 7 wherein R 4 is hydrogen or alkyl containing 1-3 carbon atoms, R 5 is hydrogen or alkyl containing 1-3 carbon atoms, and R 7 is hydrogen or alkyl containing 1-3 carbon atoms.
- the most preferred Ri is CH 3 .
- the most preferred R 3 is CH 2 -Q, wherein Q is methoxy.
- the most preferred aryl is phenyl.
- the most preferred halo is fluoro.
- the most preferred compounds include: (R)-2-acetamido-N-benzyl-3-methoxy-propionamide;
- the compounds utilized in the present invention may contain one or more asymmetric carbons and may exist in racemic and optically active forms.
- the configuration around each asymmetric carbon can be either the D or L form. It is well known in the art that the configuration around a chiral carbon atoms can also be described as R or S in the Cahn-Prelog-lngold nomenclature system. All of the various configurations around each asymmetric carbon, including the various enantiomers and diastereomers as well as racemic mixtures and mixtures of enantiomers, diastereomers or both are contemplated by the present invention.
- R, R 1 , R 2 , R 3 , R 4 , R 5 , Re, R'e, R?, Rs, Rso Z and Y are as defined previously.
- the term configuration shall refer to the configuration around the carbon atom to which R 2 and R 3 are attached, even though other chiral centers may be present in the molecule. Therefore, when referring to a particular configuration, such as D or L, it is to be understood to mean the D or L stereoisomer at the carbon atom to which R 2 and R 3 are attached. However, it also includes all possible enantiomers and diastereomers at other chira! centers, if any, present in the compound.
- the compounds of the present invention are directed to all the optical isomers, i.e., the compounds of the present invention are either the L- stereoisomer or the D-stereoisomer (at the carbon atom to which R 2 and R 3 are attached). These stereoisomers may be found in mixtures of the L and D stereoisomer, e.g., racemic mixtures. The D stereoisomer is preferred. In lacosamide, the D steroisomer corresponds to the R enantiomer according to the R, S terminology.
- the compounds of Formulae (Ib) or/and (lib), in particular lacosamide, may be substantially enantiopure.
- substantially enantiopure means preferably at least 88%, more preferably at least 90%, most preferably at least 95, 96, 97, 98, or 99% enantiomeric purity.
- the present compounds may form addition salts as well. All of these forms are contemplated to be within the scope of this invention including mixtures of the stereoisomeric forms.
- the compounds utilized in the present invention are useful as such as depicted in the Formulae (Ib) or/and (lib) or can be employed in the form of salts in view of its basic nature by the presence of the free amino group.
- the compounds of Formulae (Ib) or/and (lib) form salts with a wide variety of acids, inorganic and organic, including pharmaceutically acceptable acids.
- the salts with therapeutically acceptable acids are of course useful in the preparation of formulation where enhanced water solubility is most advantageous.
- These pharmaceutically acceptable salts have also therapeutic efficacy.
- These salts include salts of inorganic acids such as hydrochloric, hydroiodic, hydrobromic, phosphoric, metaphosphoric, nitric acid and sulfuric acids as well as salts of organic acids, such as tartaric, acetic, citric, malic, benzoic, perchloric, glycolic, gluconic, succinic, aryl sulfonic, (e.g., p-toluene sulfonic acids, benzenesulfonic), phosphoric, malonic, and the like.
- inorganic acids such as hydrochloric, hydroiodic, hydrobromic, phosphoric, metaphosphoric, nitric acid and sulfuric acids
- organic acids such as tartaric, acetic, citric, malic, benzoic, perchloric, glycolic, gluconic, succinic, aryl sulfonic, (e.g., p-to
- the present invention is further directed to a method for the prevention, alleviation or/and treatment of a disease that is treated with an antipsychotic, in particular psychosis, more particular schizophrenia, in an add-on therapy to at least one antipsychotic agent by administration of at least one compound of Formulae (Ib) or/and (lib) to a subject in need thereof.
- the method of the present invention comprises
- the at least one antipsychotic agent useful for the prevention, alleviation or treatment of psychosis may be a dopamine antagonist, preferably a D 2 antagonist, more preferably an atypical antipsychotic agent, even more preferably an atypical antipsychotic as defined above, and most preferably the agent is clozapine, risperidone, aripiprazole, quetiapine, olanzapine, ziprasidone, sulpiride, amisulpride or/and zotepine.
- the at least one compound of Formulae (Ib) or/and (lib) and the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis is administered in the form of one composition (single dose form).
- the method of the present invention comprises the administration of a separate dose form comprising (i) a first composition comprising at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis, and (ii) a second composition comprising at least one compound of Formulae
- a commercially available composition of an antipsychotic agent useful for prevention, alleviation or/and treatment of psychosis may be administered to a subject in need thereof. Therefore, in this preferred embodiment, the method of the present invention for prevention, alleviation or/and treatment of a disease that is treated with an antipsychotic, in particular psychosis, comprises administration of a pharmaceutical composition comprising at least one compound according to Formula (Ib) or/and Formula (lib) and not comprising an antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis to a subject receiving a commercially available composition containing an antipsychotic agent for prevention, alleviation or/and treatment of psychosis.
- a pharmaceutical composition comprising at least one compound according to Formula (Ib) or/and Formula (lib) and not comprising an antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis to a subject receiving a commercially available composition containing an antipsychotic agent for prevention, alleviation or/and treatment of psychosis.
- the compounds according to Formulae (Ib) or/and (lib) may also be useful in an add-on therapy for disorders or/and diseases other than schizophrenia which are treated by antipsychotic agents. Therefore, yet another subject of the present invention is an add-on therapy for the prevention, alleviation or/and treatment of bipolar disorder, autism, psychosis in diseases other than schizophrenia, e.g. in Alzheimer's disease, or/and attention deficit hyperactivity disorder, by administration of a pharmaceutical composition of the present invention.
- the compounds according to Formulae (Ib) or/and (lib) may also be used for the preparation of a pharmaceutical composition useful for the prevention, alleviation or/and treatment in an add-on therapy for disorders or/and diseases other than schizophrenia which can be treated by antipsychotic agents, such as bipolar disorder, autism, psychosis in diseases other than schizophrenia, e.g. in Alzheimer's disease, or/and attention deficit hyperactivity disorder.
- antipsychotic agents such as bipolar disorder, autism, psychosis in diseases other than schizophrenia, e.g. in Alzheimer's disease, or/and attention deficit hyperactivity disorder.
- the pharmaceutical composition of the present invention as described herein for treatment of schizophrenia may also be used for the prevention, alleviation or/and treatment in an addon therapy for disorders or/and diseases other than schizophrenia which can be treated by antipsychotic agents, such as bipolar disorder, autism, psychosis in diseases other than schizophrenia, e.g. in Alzheimer's disease, or/and attention deficit hyperactivity disorder.
- the compounds according to Formulae (Ib) or/and (lib) may also be useful in an add-on therapy to at least one antipsychotic agent for the treatment of psychosis other than psychosis in schizophrenia. Therefore, yet another subject of the present invention is an add-on therapy to at least one antipsychotic agent for the prevention, alleviation or/and treatment of psychosis associated with e.g.
- bipolar disorder autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia, Huntington's Disease, Tourette's syndrom, Parkinson's disease or/and dopaminergic therapy of Parkinson's disease, by administration of a pharmaceutical composition of the present invention.
- the compounds according to Formulae (Ib) or/and (lib) may also be used for the preparation of a pharmaceutical composition useful for the prevention, alleviation or/and treatment in an add-on therapy to at least one antipsychotic agent for the treatment of psychosis associated with e.g. bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia, Huntington's Disease, Tourette's syndrom, Parkinson's disease or/and dopaminergic therapy of Parkinson's disease.
- psychosis associated with e.g. bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder
- composition of the present invention as described herein may also be used for the prevention, alleviation or/and treatment in an add-on therapy for the treatment of psychosis associated with e.g. bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia, Huntington's Disease, Tourette's syndrom, Parkinson's disease, or/and dopaminergic therapy of Parkinson's disease.
- psychosis associated with e.g. bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia
- the compound utilized in the present invention is used in therapeutically effective amounts.
- the physician will determine the dosage of the present therapeutic agents which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary with the patient under treatment, the age of the patient, the type of malady being treated. He will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the circumstances is reached. When the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally.
- the compounds are useful in the same manner as comparable therapeutic agents and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents.
- Typical doses of antipsychotic agents administered to a subject in need thereof in the add-on therapy to at least one antipsychotic agent of the present invention are the doses of the dopamine antagonists as given above or are the following doses: olanzapine 5-20 mg/day, clozapine 100-900 mg/day, quetiapine 100-800 mg/day, risperidone 1-16 mg/day, aripiprazole 3-30 mg/day, ziprasidone 40-160 mg/day, sulpiride 300-1600 mg/day, amisulpride 50-1200 mg/day, zotepine 75-450 mg/day.
- Such doses may also be included in the pharmaceutical composition of the present invention, or/and may be used for the preparation of a pharmaceutical composition of the present invention.
- the physician is able to determine the administration route of the at least one agent useful for the prevention, alleviation or/and treatment of psychosis, which may be the same or different to the administration route of the at least one compound of the present invention of Formulae (Ib) or/and (lib).
- Typical administration routes of the at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis are oral, intravenous, intramuscular, intrathecal or subcutaneous routes. Oral or/and intravenous administration is preferred.
- the compounds of Formulae (Ib) or/and (lib) of the present invention are administered in amounts ranging from about 1 mg to about 10 mg per kilogram of body weight per day.
- This dosage regimen may be adjusted by the physician to provide the optimum therapeutic response.
- Patients in need thereof may be treated with doses of the compound of the present invention of at least 50 mg/day, preferably of at least 100 mg, more preferably at least 200 mg/day, even more preferably of at least 300 mg/day and most preferably of at least 400 mg/day.
- a patient in need thereof may be treated with doses at a maximum of 6 g/day, more preferably a maximum of 1 g/day and most preferably a maximum of 600 mg/day. In some cases, however, higher or lower doses may be needed.
- the daily doses are increased until a predetermined daily dose is reached which is maintained during the further treatment.
- several divided doses may be administered daily.
- three doses per day may be administered, preferably two doses per day. It is more preferred to administer a single dose per day.
- an amount of the compounds of the present invention may be administered which results in a plasma concentration of 0.1 to 15 ⁇ g/ml (trough) and 5 to 18.5 ⁇ g/ml (peak), calculated as an average over a plurality of treated subjects.
- the compounds of Formulae (Ib) or/and (lib) may be administered in a convenient manner, such as by oral, intravenous (where water soluble), intramuscular, intrathecal or subcutaneous routes. Oral or/and i.v. administration is preferred.
- composition of the present invention may be prepared for the treatment regimen as described above, in particular for the treatment with doses as described above, to effect plasma concentrations as described above, for administration periods or/and administration routes as specified in the embodiments of the present invention as described above.
- compositions of the present invention comprising the at least one antipsychotic agent for the prevention, alleviation or/and treatment of psychosis, in particular schizophrenia, is formulated with common carriers, diluents or/and auxiliary substances known to a person skilled in the art.
- the first composition comprising at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis and the second composition comprising at least one compound of Formulae (Ib) or/and (lib) may comprise carriers, diluents or/and auxiliary substances which are independently from each other, identical or different in the first composition comprising at least one antipsychotic agent useful for the prevention, alleviation or/and treatment of psychosis and the second composition comprising at least one compound of Formulae (Ib) or/and (lib).
- the compounds of Formulae (Ib) or/and (Mb) may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly into the food or the diet.
- the active compound of Formulae (Ib) or/and (lib) may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 1% of active compound of Formulae (Ib) or/and (lib).
- compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit.
- amount of active compound of Formulae (Ib) or/and (lib) in such therapeutically useful compositions is such that a suitable dosage will be obtained.
- Preferred compositions or preparations according to the present invention contains between about 10 mg and 6 g active compound of Formulae (Ib) or/and (lib).
- the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, com starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring.
- a binder such as gum tragacanth, acacia, com starch or gelatin
- excipients such as dicalcium phosphate
- a disintegrating agent such as corn starch, potato starch, alginic acid and the like
- a lubricant such as magnesium stearate
- a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermin
- any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and formulations.
- sustained release dosage forms are contemplated wherein the active ingredient is bound to an ion exchange resin which, optionally, can be coated with a diffusion barrier coating to modify the release properties of the resin.
- the active compound may also be administered parenterally or intraperitoneal ⁇ .
- Dispersions can also be prepared in glycerol, liquid, polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying the freeze-drying technique plus any additional desired ingredient from previously sterile-filtered solution thereof.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agent, isotonic and absorption delaying agents for pharmaceutical active substances as well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specifics for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material an the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such as active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.
- the principal active ingredient is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore described.
- a unit dosage form can, for example, contain the principal active compound in amounts ranging from about 10 mg to about 6 g. Expressed in proportions, the active compound is generally present in the carrier in an amount from about 1 to about 750 mg/ml of carrier.
- the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.
- patient refers to a warm blooded animal, and preferably mammals, such as, for example, cats, dogs, horses, cows, pigs, mice, rats and primates, including humans.
- mammals such as, for example, cats, dogs, horses, cows, pigs, mice, rats and primates, including humans.
- the preferred patient is a human.
- treat refers to preventing, curing or alleviating the patient's disease or condition.
- the compounds of the present invention are administered to a patient suffering from the aforementioned type of disorder in an effective amount. These amounts are equivalent to the therapeutically effective amounts described hereinabove.
- the following example shows the properties of lacosamide, formerly called Harkoseride, or SPM 927, potentiating the prepulse inhibition of the antipsychotic agent clozapine in mice when administered together.
- the used substance was lacosamide.
- the standard chemical nomenclature is (R)-2-acetamide-N-benzyl-3-methoxypropionamide.
- prepulse inhibition is a general model of psychosis and therefore indicative for psychosis associated with other diseases or conditions, such as psychosis associated with schizophrenia, bipolar disorder, autism, Alzheimer's disease, attention deficit hyperactivity disorder, drug or/and alcohol abuse, affective disorders, dyskinesias and related disorders, dementia, mental retardation, polydipsia/hyponatraemia, severe personality disorder, acute episodes of mania, obsessive compulsive disorder, intractable chronic insomnia, Huntington's Disease, Tourette's syndrom, Parkinson's disease, or/and dopaminergic therapy of Parkinson's disease.
- the acoustic startle is an unconditioned reflex response to an external auditory stimulation.
- PPI refers to the reduction in the startle response caused by the presentation of a low-intensity auditory stimulus prior to the startle stimulus.
- the PPI paradigm is the choice for the study of schizophrenia and antipsychotic action due to the similarities between the results from human and rodent studies.
- Antipsychotic agents such as clozapine, result in a dose-dependent increase in PPI in mice.
- an increase of PPI in normal mice may be indicative of antipsychotic efficacy.
- mice obtained from the Jackson Laboratory, Bar Harbor, Maine were received at the age of 6 weeks and were assigned unique identification numbers (tail marked). Animals were housed 4 per cage in polycarbonate cages with filter tops and acclimated for 7 days. All animals were examined, handled, and weighed prior to initiation of the study to assure adequate health and suitability and to minimize non-specific stress associated with manipulation.
- Lacosamide was dissolved in Saline (0.9% NaCI in sterile H 2 O).
- Clozapine was dissolved in 1% Tween 80 in sterile H 2 O at a final pH of 6.0. All compounds were administered intraperitoneal (ip) (volume injection: 10 ml/kg). Lacosamide was administered at doses of 1, 10 and 30 mg/kg and Clozapine at a dose of 3 mg/kg. Doses are expressed as mg of salt.
- Control mice were administered saline (vehicle 1, VEH 1) or 1% Tween 80 (vehicle 2, VEH 2) at a pH of 6.0. The drug treatments were balanced across days and the animals only used once. All tests were conducted blind. All compounds were administered 30 min prior to testing.
- mice were placed in the PPI chambers (Med Associates) for a 5 min session of white noise (70 dB) habituation. After the acclimation period the test session was automatically started. The session started with an habituation block of 6 presentations of the startle stimulus alone, followed by 10 PPI blocks of 6 different types of trials. Trial types are: null (no stimuli), startle (120 dB), startle plus prepulse (4, 8 and 12 dB over background noise i.e. 74, 78 or 82 dB) and prepulse alone (82 dB). Trial types were presented at random within each block. Each trial started with a 50 ms null period during which baseline movements are recorded.
- mice Twelve animals were tested in each group. A total of 108 mice were tested using following design:
- VEH1/VEH2 lacosamide [3 mg/kg] / VEH2 lacosamide [10 mg/kg] / VEH2 lacosamide [30 mg/kg] / VEH2
- the data obtained provide a basis for clinical trials in humans using lacosamide as an add-on therapy for the treatment of psychosis, in particular of schizophrenia or psychosis associated with schizophrenia or/and other diseases or conditions.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64741005P | 2005-01-28 | 2005-01-28 | |
EP05001843A EP1688137A1 (fr) | 2005-01-28 | 2005-01-28 | SPM 927 pour la thérapie adjuvante de la schizophrenie |
PCT/EP2006/000722 WO2006079547A2 (fr) | 2005-01-28 | 2006-01-27 | Lacosamide pour traitement d'appoint |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1841417A2 true EP1841417A2 (fr) | 2007-10-10 |
Family
ID=36636204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06706448A Withdrawn EP1841417A2 (fr) | 2005-01-28 | 2006-01-27 | Spm 927 pour la thérapie adjuvante de la schizophrenie |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1841417A2 (fr) |
JP (1) | JP2008528532A (fr) |
KR (1) | KR20070096058A (fr) |
AR (1) | AR057643A1 (fr) |
AU (1) | AU2006208630B2 (fr) |
BR (1) | BRPI0607043A2 (fr) |
CA (1) | CA2595330A1 (fr) |
EA (1) | EA015566B1 (fr) |
IL (1) | IL183973A0 (fr) |
MX (1) | MX2007009070A (fr) |
NO (1) | NO20074361L (fr) |
WO (1) | WO2006079547A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
EP1873527A1 (fr) | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Procédé d'identification des modulateurs CRMP |
EP1920780A1 (fr) * | 2006-10-12 | 2008-05-14 | Schwarz Pharma Ag | Composés peptidiques pour le traitement des maladies liées à l'hyperexcitabilité |
TWI397417B (zh) * | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
EP2214657A1 (fr) | 2007-10-23 | 2010-08-11 | UCB Pharma GmbH | Composés pour le traitement de conditions de démyélinisation |
WO2010077916A1 (fr) * | 2008-12-16 | 2010-07-08 | Eurand, Inc. | Compositions comportant de la melpèrone |
EP2468261A1 (fr) | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation de lacosamide |
BR112013013525A2 (pt) | 2010-12-02 | 2016-10-18 | Ucb Pharma Gmbh | formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central |
CN115813888A (zh) | 2016-12-20 | 2023-03-21 | 罗曼治疗系统股份公司 | 包含阿塞那平的透皮治疗系统 |
EP3558276A1 (fr) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Système thérapeutique transdermique contenant de l'asénapine et un polysiloxane ou un polyisobutylène |
JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
WO2019113084A1 (fr) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Formes cristallines et leurs procédés de production |
SG11202005016SA (en) | 2017-12-05 | 2020-06-29 | Sunovion Pharmaceuticals Inc | Nonracemic mixtures and uses thereof |
MX2020014286A (es) | 2018-06-20 | 2021-03-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
KR20220018004A (ko) | 2019-06-04 | 2022-02-14 | 선오비온 파마슈티컬스 인코포레이티드 | 조절 방출 제형 및 이의 용도 |
US11278634B1 (en) | 2021-02-12 | 2022-03-22 | Extrovis Ag | Stable parenteral composition of lacosamide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5378729A (en) * | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
US5773475A (en) | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
DK1243262T3 (da) | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
EP1243263B1 (fr) | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Nouvelle utilisation d'une classe de composés peptidiques pour le traitement de l'allodynie ou d'autres types de douleurs chroniques ou fantômes |
-
2006
- 2006-01-27 EA EA200701594A patent/EA015566B1/ru not_active IP Right Cessation
- 2006-01-27 MX MX2007009070A patent/MX2007009070A/es active IP Right Grant
- 2006-01-27 BR BRPI0607043-4A patent/BRPI0607043A2/pt not_active IP Right Cessation
- 2006-01-27 AR ARP060100304A patent/AR057643A1/es not_active Application Discontinuation
- 2006-01-27 CA CA002595330A patent/CA2595330A1/fr not_active Abandoned
- 2006-01-27 EP EP06706448A patent/EP1841417A2/fr not_active Withdrawn
- 2006-01-27 AU AU2006208630A patent/AU2006208630B2/en not_active Ceased
- 2006-01-27 WO PCT/EP2006/000722 patent/WO2006079547A2/fr active Application Filing
- 2006-01-27 JP JP2007552583A patent/JP2008528532A/ja not_active Withdrawn
- 2006-01-27 KR KR1020077019581A patent/KR20070096058A/ko not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183973A patent/IL183973A0/en unknown
- 2007-08-27 NO NO20074361A patent/NO20074361L/no not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2006079547A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2595330A1 (fr) | 2006-08-03 |
AU2006208630A1 (en) | 2006-08-03 |
AR057643A1 (es) | 2007-12-12 |
AU2006208630B2 (en) | 2011-09-29 |
IL183973A0 (en) | 2008-12-29 |
BRPI0607043A2 (pt) | 2009-08-04 |
KR20070096058A (ko) | 2007-10-01 |
NO20074361L (no) | 2007-10-26 |
WO2006079547A2 (fr) | 2006-08-03 |
MX2007009070A (es) | 2007-09-12 |
EA200701594A1 (ru) | 2008-02-28 |
WO2006079547A3 (fr) | 2006-09-21 |
EA015566B1 (ru) | 2011-10-31 |
JP2008528532A (ja) | 2008-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006208630B2 (en) | SPM 927 for add-on therapy of schizophrenia | |
US20060252749A1 (en) | Lacosamide for add-on therapy of psychosis | |
JP6158376B2 (ja) | 相乗的抗痙攣効果を有する医薬組成物 | |
AU2007260208B2 (en) | Peptide compounds for treating refractory status epilepticus | |
JP5038892B2 (ja) | 本態性振せん及び他の振せん症候群を治療するためのペプチド化合物の新しい使用 | |
AU2005232395B2 (en) | Use of peptidic compounds for the prophylaxis and treatment of chronic headache | |
MXPA06013300A (es) | Uso novedoso de compuestos peptidicos para tratar discinesia. | |
US20050277596A1 (en) | Novel use of peptide compounds for treating amyotrophic lateral sclerosis | |
ZA200705892B (en) | SPM 927 for add-on therapy of schizophrenia | |
AU2005251465A1 (en) | Novel use of peptide compounds for treating pain in trigeminal neuralgia | |
WO2004080444A2 (fr) | Methodes de traitement de troubles des voies urinaires inferieures et des troubles associes tels que la vulvodynie et la vestibulite vulvaire a l'aide de modulateurs des canaux calciques contenant des sous-unites cav2.2 | |
US20050119249A1 (en) | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists | |
EP1778211A1 (fr) | Methodes et substances de traitement d'une maladie mentale | |
EP1576985A1 (fr) | Utilisation d'antagonistes, d'agonistes partiels ou d'agonistes inverses des recepturs D4 et 5-HT2A | |
AU2003263357B2 (en) | Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines | |
KR20070030781A (ko) | 근위축성 측삭 경화증의 치료를 위한 펩티드 화합물의신규한 용도 | |
KR20070018067A (ko) | 삼차 신경통의 통증을 치료하기 위한 펩티드 화합물의신규한 용도 | |
ZA200505142B (en) | Methods of treating non-painful bladder disorders using &2.d subunit calcium channel modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070629 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1103038 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20090819 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: UCB PHARMA GMBH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1103038 Country of ref document: HK |
|
INTG | Intention to grant announced |
Effective date: 20130820 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20140103 |